Print

Novuspharma SpA (IT:NOV) Release: Pixantrone Research Study Reveals No Increase In Anthracycline-Induced Heart Damage 
10/19/2005 5:10:49 PM

SEATTLE, Nov. 19 /PRNewswire-FirstCall/ -- Novuspharma S.p.A. (Novuspharma) (Nuovo Mercato: NOV.MI) announced the results of a preliminary preclinical study on Pixantrone together with results from three other studies of Pixantrone, which were presented in a poster session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, on Tuesday, November 18. In June, Cell Therapeutics, Inc. (CTI) and Novuspharma announced they had entered into a merger agreement.

For more information on the study, refer to the Novuspharma website at: http://www.novuspharma.com/nov/investorinfo/releases/

About Cell Therapeutics, Inc.

Based in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com/.

Cell Therapeutics, Inc.

CONTACT: investors, Leah Grant, +1-206-282-7100, or fax,+1-206-272-4010, or invest@ctiseattle.com, or media, Candice Douglass,+1-206-272-4472, or fax, +1-206-272-4010, or media@ctiseattle.com, both ofCell Therapeutics, Inc.


//-->